Peptidomimetic blockade of MYB in acute myeloid leukemia
MYB activity is a key factor for the maintenance of acute myeloid leukemias but it is also a difficult target. Here, the authors develop a peptidomimetic (MYBMIM) that prevents the interaction of the trans-activation domain of MYB with the KIX domain of CBP/P300 and inhibits leukaemia growth.
Main Authors: | Kavitha Ramaswamy, Lauren Forbes, Gerard Minuesa, Tatyana Gindin, Fiona Brown, Michael G. Kharas, Andrei V. Krivtsov, Scott A. Armstrong, Eric Still, Elisa de Stanchina, Birgit Knoechel, Richard Koche, Alex Kentsis |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2018-01-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-017-02618-6 |
Similar Items
-
Convergent organization of aberrant MYB complex controls oncogenic gene expression in acute myeloid leukemia
by: Sumiko Takao, et al.
Published: (2021-02-01) -
Therapeutic reactivation of protein phosphatase 2A in acute myeloid leukemia
by: Kavitha eRamaswamy, et al.
Published: (2015-02-01) -
Calculation of the free energy and cooperativity of protein folding.
by: Alex Kentsis, et al.
Published: (2007-05-01) -
Regulation of MYB by distal enhancer elements in human myeloid leukemia
by: Mengjia Li, et al.
Published: (2021-02-01) -
Development of Bioactive Peptidomimetics
by: She, Fengyu
Published: (2018)